Vertex Pharmaceuticals Inc / Ma
A global biotech developing transformative medicines for serious diseases, Vertex Pharmaceuticals is best known for its cystic fibrosis franchise — KALYDECO, ORKAMBI, SYMDEKO, TRIKAFTA, and ALYFTREK — which treats most people with CF in key Western markets. The company also makes CASGEVY, a CRISPR gene-editing therapy for sickle cell disease and beta thalassemia, and JOURNAVX, a non-opioid pain signal inhibitor for acute pain. Its pipeline targets kidney disease, chronic pain, and type 1 diabetes.
Granted 55.2K · Sold 40.0K
Granted 66.0K · Sold 60.5K
Granted 30.5K · Sold 23.5K
Granted 17.5K · Sold 12.2K
Granted 154.4K · Sold 137.1K
Granted 11.2K
Sold 3.8K
Granted 12.8K · Sold 7.8K
Granted 16.7K · Sold 24.7K
Granted 13.2K · Sold 8.6K
Granted 11.8K · Sold 10.0K
Granted 472
Granted 2.6K · Sold 6.3K
Granted 6.1K · Sold 4.2K
Granted 943 · Sold 584
Granted 943
Granted 472
Granted 472
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kewalramani ReshmaCEO & President, Director · 20 transactions | -8.6% | 106.0K | 55.2K | — | 40.0K |
| Sachdev AmitEVP Chief Patient & Ext Af Off · 18 transactions | -5.2% | 65.8K | 66.0K | — | 60.5K |
| Wagner Charles F JrEVP, CO & FO · 11 transactions | -9% | 47.0K | 30.5K | — | 23.5K |
| Tatsis OuraniaEVP, Chief Reg. & Quality Off. · 14 transactions | -8.7% | 46.8K | 17.5K | — | 12.2K |
| Leiden Jeffrey MExecutive Chairman, Director · 26 transactions | +44% | 35.2K | 154.4K | — | 137.1K |
| Altshuler DavidEVP, Chief Scientific Officer · 2 transactions | +48.1% | 34.5K | 11.2K | — | — |
| Liu JoyEVP and Chief Legal Officer · 4 transactions | +61.6% | 20.0K | — | — | 3.8K |
| Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. · 12 transactions | -4.8% | 18.4K | 12.8K | — | 7.8K |
| Bozic CarmenEVP and CMO · 17 transactions | -53.1% | 15.3K | 16.7K | — | 24.7K |
| Biller JonathanEVP and Chief Legal Officer · 15 transactions | -22.4% | 13.7K | 13.2K | — | 8.6K |
| McKechnie DuncanEVP, Chief Commercial Officer · 11 transactions | -22.6% | 12.5K | 11.8K | — | 10.0K |
| Garber Alan MDirector · 1 transaction | +6.9% | 7.3K | 472 | — | — |
| Bunnage Mark E.EVP, Chief Scientific Officer · 10 transactions | — | 7.3K | 2.6K | — | 6.3K |
| Ambrose KristenSVP & Chief Accounting Officer · 12 transactions | -15.6% | 6.6K | 6.1K | — | 4.2K |
| Carney LloydDirector · 1 transaction | -11.2% | 6.3K | — | — | — |
| Bhatia Sangeeta N.Director · 3 transactions | +7.9% | 4.9K | 943 | — | 584 |
| McKenzie DianaDirector · 2 transactions | +38.7% | 3.4K | 943 | — | — |
| Schneider JenniferDirector · 2 transactions | +27.5% | 2.2K | 472 | — | — |
| Thornberry NancyDirector · 2 transactions | +3.6% | 2.1K | 472 | — | — |
| Upadhyay SuketuDirector · 1 transaction | -33.8% | 1.6K | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -339.2K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.